H. Fung

发表

Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.

S. Mineishi, M. Zaidi, B. Blazar, 2016, Blood.

Solid cancers after bone marrow transplantation.

A. Nademanee, J. Niland, A. Krishnan, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Approach to Hodgkin's lymphoma in the new millennium

A. Nademanee, H. Fung, 2002, Hematological oncology.

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

A. Nademanee, A. Krishnan, M. Slovak, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation.

D. Horsman, D. Hogge, D E Horsman, 1998, Blood.

Loss of CD26 protease activity in recipient mice during hematopoietic stem cell transplantation results in improved transplant efficiency

C. Seong, H. Fung, E. Yoo, 2013, Transfusion.

A simplified technique for delivering total body irradiation (TBI) with improved dose homogeneity.

W. Sensakovic, J. Chu, R. Abrams, 2012, Medical physics.

Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia

S. Forman, H. Fung, 2003 .

Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.

A. Nademanee, J. Niland, A. Krishnan, 2000, Blood.

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Michael L. Wang, R. Houot, M. Kersten, 2020, The New England journal of medicine.

Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma.

Sonali M. Smith, R. Fisher, Y. Oki, 2018 .

relapsed non-Hodgkin lymphoma by autologous stem cell transplantation in patients with poor-risk or combination with high-dose etoposide and cyclophosphamide followed A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group.

A. Nademanee, J. Niland, G. Somlo, 1997, Blood.

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.

A. Krishnan, P. Hari, R. Kyle, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cellular therapies supplement: strategies for improving transplant efficiency in the context of cellular therapeutics

H. Fung, Kent W. Christopherson 2nd, A. Jimenez, 2011, Transfusion.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

TRANSPLANTATION Programming of donor T cells using allogeneic d -like ligand 4 – positive dendritic cells to reduce GVHD in mice

S. Mineishi, M. Zaidi, B. Blazar, 2016 .

Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long‐term ex vivo culture

S. Ramin, R. Zabriskie, H. Fung, 2008, Transfusion.

High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission.

A. Nademanee, J. Niland, A. Krishnan, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1.

H. Fung, K. Christopherson, S. Gregory, 2012, Experimental hematology.

Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.

H. Fung, K. Christopherson, L. Tan, 2011, Experimental hematology.

Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.

A. Nademanee, A. Krishnan, M. Slovak, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

196 Allogeneic bone marrow transplantation for adults with primary myelodysplastic syndrome: Evaluation of prognostic factors

D. Horsman, D. Hogge, H. Fung, 1997 .

Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma.

J. Niland, K. van Besien, G. Somlo, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Crypt loss is a marker of clinical severity of acute gastrointestinal graft‐versus‐host disease

A. Keshavarzian, S. Jakate, J. Melson, 2007, American journal of hematology.

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

A. Nademanee, A. Krishnan, S. Forman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

David D. Smith, A. Nademanee, A. Krishnan, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Bone Marrow Transplantation for BCR-ABL Positive Acute Lymphoblastic Leukemia

J. Niland, M. Amylon, M. Slovak, 2001 .

Non-Hodgkins Lymphoma (NHL) by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Combination with High-Dose Etoposide and Cyclophosphamide Followed A Phase I/II Trial of High-Dose Yttrium 90 ibritumomab tiuxetan in

David D. Smith, A. Nademanee, A. Krishnan, 2013 .

HEMATOPOIESIS AND STEM CELLS Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice

Changhong Li, Yuting Gu, M. Jin, 2017 .

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Neutropenia Recovery Linked to Filgrastim Initiation Timing After Autologous Hematopoietic Stem-Cell Transplantation

H. Fung, Frcpe, 2016 .

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

G. Salles, D. Maloney, V. Plaks, 2020 .

Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy.

D. Ramies, A. Younes, K. Blum, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of allogeneic bone marrow transplantation on recipient bone mineral density: A prospective study.

J. Niland, A. Krishnan, R. Bhatia, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation

H. Fung, G. Peksa, K. Schultz, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.

A. Nademanee, J. Niland, M. Amylon, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.

A. Nademanee, Yan Liu, L. Robison, 2005, Blood.

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

G. Salles, S. de Vos, D. Maloney, 2021, The Lancet. Oncology.

Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission.

A. Nademanee, J. Niland, A. Krishnan, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.

Sonali M. Smith, R. Fisher, Y. Oki, 2019, Clinical lymphoma, myeloma & leukemia.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

C. Hofmeister, A. Krishnan, S. Singhal, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Engineering of Chimeric Antigen Receptor T Cells with integrin αEβ7 Results in Augmented Therapeutic Efficacy against E-cadherin positive tumor

J. Issa, E. Dulaimi, M. Tao, 2019, bioRxiv.

Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.

Yuting Gu, M. Jin, Yanyun Zhang, 2017, Blood.

Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.

P. Venugopal, H. Fung, S. Gregory, 2011, Clinical lymphoma, myeloma & leukemia.

Interleukin-2 A fter A utologous S tem-Cell T ransplantation f or Adult P atients W ith A cute M yeloid L eukemia i n F irst Complete R emission

A. Nademanee, J. Niland, A. Krishnan, 2003 .

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

M. Amylon, M. Slovak, R. Negrin, 1999, Leukemia.

Older patients with myeloma derive similar benefit from autologous transplantation.

A. Krishnan, S. Lonial, P. Hari, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.

A. Nademanee, J. Niland, A. Krishnan, 2000, Clinical lymphoma.

The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation

S. Mineishi, Zhenjiang Bai, Yanyun Zhang, 2016, The Journal of Immunology.

Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.

A. Nademanee, A. Krishnan, G. Somlo, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

W. Wood, M. Sorror, F. Baron, 2017, Blood.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).

G. Salles, D. Maloney, V. Plaks, 2021 .

Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

G. Salles, D. Maloney, V. Plaks, 2020 .

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia

J. Issa, J. Jelinek, W. Chung, 2019, Clinical Epigenetics.

Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies

M. Angelopoulou, G. Somlo, S. Forman, 2004, Bone Marrow Transplantation.

Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma

W. Wood, Z. DeFilipp, B. Shaw, 2018, Cancer.

Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors

Patrick M Liu, A. Lammerich, C. Abboud, 2018, Supportive Care in Cancer.

High-dose chemotherapy with autologous stem cell rescue for relapse after allo-SCT in multiple myeloma

H. Fung, H. Tuncer, S. Gregory, 2011, Bone Marrow Transplantation.

One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Michael L. Wang, R. Houot, M. Kersten, 2020 .

A phase 1 dose‐escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

A. Younes, K. Blum, P. Foster, 2015, British journal of haematology.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, J. Klein, 2015, Biology of Blood and Marrow Transplantation.

Posttraumatic stress symptoms predict impaired neutrophil recovery in stem cell transplant recipients

Alyson K. Zalta, S. Hobfoll, H. Fung, 2015, Psycho-oncology.

Toxic Epidermal Necrolysis and Graft versus Host Disease after Hematopoietic and Liver Transplantation : A Review Review Article

H. Fung, S. Poulakidas, A. Kowal-Vern, 2018 .

Toxic Epidermal Necrolysis and Graft versus Host Disease after Hematopoietic and Liver Transplantation : A Review Research Article

H. Fung, S. Poulakidas, A. Kowal-Vern, 2018 .

Primary CNS lymphoma

P. Pancari, H. Fung, P. Kropf, 2017 .

Gastrointestinal side effects and adequacy of enteral intake in hematopoietic stem cell transplant patients.

S. Foley, H. Fung, Cheryl A. Bacon, 2015, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

The impact of posttraumatic stress symptoms on social support and social conflict during hematopoietic stem cell transplant

Teresa A. Lillis, S. Hobfoll, T. Lillis, 2018, Journal of psychosocial oncology.

Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma

Y. Oki, R. Alpaugh, S. Barta, 2020 .

In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice.

C. Bueso-Ramos, L. Boggio, H. Fung, 2011, Experimental hematology.

Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost,

G. Tricot, J. Kanda, J. Liesveld, 2011 .

Acute monocytic leukemia: a single institution experience.

D. Horsman, D. Reece, H. Fung, 1995, Leukemia & lymphoma.

Anger, provider responses, and pain: prospective analysis of stem cell transplant patients.

S. Hobfoll, J. Burns, H. Fung, 2015, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

A. Nademanee, A. Krishnan, S. Forman, 2006 .

Sequential single-agent obatoclax mesylate (GX15–070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma

M. Berger, A. Goy, A. Mato, 2014, Leukemia & lymphoma.

90Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose Therapy (HDT) Followed by Autologous Stem Cell Transplant (ASCT) May Improve Survival in Patients with Poor-Risk Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Retrospective Comparative Analysis.

A. Nademanee, A. Krishnan, S. Forman, 2006 .

Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.

A. Nademanee, J. Winter, I. Flinn, 2007, Current stem cell research & therapy.

Assessing the impact of comorbidities on autologous hematopoietic cell transplant (AHCT) outcomes using the hematopoietic cell transplant-comorbidity index (HCT-CI) in lymphoma

P. Venugopal, H. Fung, S. Gregory, 2007 .

Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma – does it matter?

H. Fung, J. Maciejewski, S. Nathan, 2010, Clinical pharmacology : advances and applications.

Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile.

S. Miller, M. Mulligan, H. Fung, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD38 Expression Loss in Multiple Myeloma Treated with Daratumumab

E. Dulaimi, H. Fung, N. Hotchandani, 2016 .

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)

G. Salles, D. Maloney, V. Plaks, 2020 .

Gastrointestinal side effects and adequacy of enteral intake in hematopoietic stem cell transplant patients.

S. Foley, H. Fung, Cheryl A. Bacon, 2015, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, D. Maloney, 2015, Biology of Blood and Marrow Transplantation.

Clinical Pharmacology: Advances and Applications Dovepress Dovepress Induction Chemotherapy before Autologous Stem Cell Transplantation for Symptomatic Plasma Cell Myeloma – Does It Matter?

H. Fung, J. Maciejewski, S. Nathan, 2022 .